ArticleEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences2013
Quercetin solid lipid microparticles: a flavonoid for inhalation lung delivery.
Article in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Multi-Target Antitumor Effects of Natural Products and Approved Drug Repurposing in Non-Small Cell Lung Cancer: Advances in Mechanisms, Combination Regimens, Delivery System Optimization, and Clinical Challenges.International journal of molecular sciences · 2026Review
- Quercetin-Eudragit® polymer complexes with enhanced loading, solubility, stability, and site-specific targeting.Therapeutic delivery · 2025Article
- Drug Release from Lipid Microparticles-Insights into Drug Incorporation and the Influence of Physiological Factors.Pharmaceutics · 2024Article
- Development of nanoparticles incorporated with quercetin and ACE2-membrane as a novel therapy for COVID-19.Journal of nanobiotechnology · 2024Article
- Towards More Precise Targeting of Inhaled Aerosols to Different Areas of the Respiratory System.Pharmaceutics · 2024Review
- Natural Products-Based Inhaled Formulations for Treating Pulmonary Diseases.International journal of nanomedicine · 2024Review
- Inhalation Dosage Forms: A Focus on Dry Powder Inhalers and Their Advancements.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Repositioned Natural Compounds and Nanoformulations: A Promising Combination to Counteract Cell Damage and Inflammation in Respiratory Viral Infections.Molecules (Basel, Switzerland) · 2023Review
- An evolving perspective on novel modified release drug delivery systems for inhalational therapy.Expert opinion on drug delivery · 2023Review
- Article
- Inhalable Formulations to Treat Non-Small Cell Lung Cancer (NSCLC): Recent Therapies and Developments.Pharmaceutics · 2022Review
- Flavonoids-Based Delivery Systems towards Cancer Therapies.Bioengineering (Basel, Switzerland) · 2022Review
- Spray Dried Rugose Lipid Particle Platform for Respiratory Drug Delivery.Pharmaceutical research · 2022Article
- Modern Nanocarriers as a Factor in Increasing the Bioavailability and Pharmacological Activity of Flavonoids.Applied biochemistry and microbiology · 2022Article
- Pharmaceutical strategies to extend pulmonary exposure of inhaled medicines.Acta pharmaceutica Sinica. B · 2021Review
- Solid Lipid Nanoparticles Produced via a Coacervation Method as Promising Carriers for Controlled Release of Quercetin.Molecules (Basel, Switzerland) · 2021Article
- COVID-19: Pathophysiology, treatment options, nanotechnology approaches, and research agenda to combating the SARS-CoV2 pandemic.Life sciences · 2020Review
- Protective efficacy of inhaled quercetin for radiation pneumonitis.Experimental and therapeutic medicine · 2017Article
- Physicochemical Characterization andTurkish journal of pharmaceutical sciences · 2017Article
- Dry Powder Inhalers: A Focus on Advancements in Novel Drug Delivery Systems.Journal of drug delivery · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe aim of the present work was to develop solid lipid microparticles (SLMs), as dry powders containing quercetin for direct administration to the lung.
methodsQuercetin microparticles were prepared by o/w emulsification via a phase inversion technique, using tristearin as the lipid component and phosphatidylcholine as an emulsifier. The quercetin SLMs were characterised for morphology, drug loading (15.5%±0.6, which corresponded to an encapsulation efficiency of 71.4%), particle size distribution, response to humidity, crystallinity, thermal behaviour and in vitro respirable fraction. Furthermore, the toxicity and the in vitro transport of the SLMs on an air liquid interface model of the Calu-3 cell line were also investigated using a modified twin-stage impinger apparatus.
resultsResults showed that quercetin SLMs could be formulated as dry powder suitable for inhalation drug delivery (20.5±3.3% fine particle fraction ≤4.46μm) that was absorbed, via a linear kinetic model across the Calu-3 monolayer (22.32±1.51% over 4h). In addition, quercetin SLMs were shown to be non-toxic at the concentrations investigated. Interestingly, no apical to basolateral transport of the micronised quercetin was observed over the period of study.
conclusionsThese observations suggest quercetin diffusion was enhanced by the presence of the lipid/emulsifying excipients in the SLMs; however further studies are necessary to elucidate the exact mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.